The role of 5-hydroxytryptophan (5-HTP) in the regulation of the sleep/wake cycle in parachlorophenylalanine (p-CPA) pretreated rat: a multiple approach study.
In the rat, the insomnia which follows the administration of parachlorophenylalanine (p-CPA), a serotonin synthesis inhibitor, is transiently reversed either by intra-cisternal injection of L-5-HTP or by an associated injection of 5-HTP and an L-aromatic-acid-decarboxylase inhibitor (benserazide). Histochemical, immunohistochemical and chemical investigations showed that 5-HTP administration does not lead to a detectable increase in cerebral 5-HT. These findings suggest that the restoration of sleep after p-CPA treatment could be mediated by the central action of 5-HTP.
Touret
M
M
Département de Médecine Expérimentale, INSERM U 52, CNRS, URA 1195, Université Claude Bernard, Lyon, France.
Sarda
N
N
Gharib
A
A
Geffard
M
M
Jouvet
M
M
D006916:5-Hydroxytryptophan / Q000008:administration & dosage / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D001345:Autoradiography; D001545:Benserazide / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects; D002946:Cisterna Magna; D010134:Fenclonine / Q000494:pharmacology*; D007150:Immunohistochemistry; D007267:Injections; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism; D012890:Sleep / Q000187:drug effects / Q000502:physiology*
D012701:Serotonin; D001545:Benserazide; D006916:5-Hydroxytryptophan; D010134:Fenclonine